Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Malignant mesothelioma (MM) is an aggressive cancer with poor prognosis, primarily linked to asbestos exposure.
• Current treatments offer limited efficacy in altering the disease's natural course.
• SRC family kinases (SFKs) are frequently hyperactivated in MM and implicated in key oncogenic pathways.

Purpose of the Study:

• To review the molecular mechanisms of SFK involvement in MM progression.
• To discuss strategies for optimizing SFK inhibitor clinical application in MM.
• To encourage further research into SFK-targeted therapies for MM.

Main Methods:

• Literature review of studies on SFKs in MM.
• Analysis of preclinical data on SFK inhibitors in MM models.
• Examination of clinical trial data for SFK inhibitors in MM patients.

Main Results:

• SFKs regulate critical MM processes including proliferation, survival, motility, and invasion.
• SFK inhibitors have demonstrated efficacy in counteracting MM features in preclinical settings.
• Dasatinib, an SFK inhibitor, has been investigated in clinical trials for MM.

Conclusions:

• SFKs are crucial drivers of MM progression and represent a viable therapeutic target.
• Optimizing SFK inhibitor strategies is essential for successful clinical translation in MM.
• Further well-designed preclinical and clinical studies are needed to fully leverage SFK inhibitors for MM treatment.